Reata Pharmaceuticals — Q2 2021 Earnings Presentation
23 slides from Reata Pharmaceuticals's earnings presentation, Aug 9, 2021
Slide 1: 2nd Quarter 2021 Financial Results and Update on Clinical Development Programs
August 9, 2021 2nd Quarter 2021 Financial Results and Update on Clinical Development Programs Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg
Slide 3: Today's Agenda
Today’s Agenda Huff, CEO Program Updates | Colin Meyer, MD, Chief R&D Officer Financial & Operational Update| Manmeet Soni, COO & CFO Concluding Remarks | Warren Huff, CEO
Slide 4: Regulatory Update on Omaveloxolone for Patients with Friedreich's ataxia
Regulatory Update on Omaveloxolone for Patients with Friedreich’s ataxia NDA: New Drug Application
Slide 5: Regulatory Update on Bardoxolone for Patients with Alport Syndrome
Regulatory Update on Bardoxolone for Patients with Alport Syndrome FDA: U.S. Food and Drug Administration; BIMO: Bioresearch monitoring; PDUFA: Prescription Drug User Fee Act
Slide 6: Mid-Cycle Communication Meeting Overview
Mid-Cycle Communication Meeting Overview Meeting focused on clinical and statistical topics Four significant issues identified, which we believe are addressable FDA invited us to address these issues in follow up submissions to the NDA Other review topics previously raised were not mentioned FDA did
Slide 7: Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline
Slide 8: Alport Syndrome
Alport Syndrome oo; |e Se caroivas | VEAGLE
Slide 9: Mid-Cycle Communication Meeting
Mid-Cycle Communication Meeting Purpose of the mid-cycle communication meeting is for the FDA to provide Sponsor with a status update on the NDA review, including any issues identified Meeting was focused on four clinical and statistical review issues that were identified as significant Acute PD eff
Slide 10: Off-Treatment Patients who Discontinued Bardoxolone Progressed at Same Rate as Placebo
4 week Off-Treatment Patients who Discontinued Bardoxolone Progressed at Same Rate as Placebo Patients in Year 2 Study Week Higher rate of eGFR decline in Year 1 explained by patients who discontinued treatment early in the study Acute eGFR increase lost by Week 36 Discontinued patients performed li
Slide 11: Treatment Duration as a Covariate in Week 104 Analysis
Treatment Duration as a Covariate in Week 104 Analysis FDA questioned, and then acknowledged, that we followed the pre-specified analysis model, which included treatment duration as a covariate During the meeting, we discussed the imputation step, which did not pre-specify use of covariates FDA sugg
Slide 12: Sensitivity Analysis for Off-Treatment Analysis Window Duration
CARDINAL pre-specified that off-treatment eGFR values be obtained ≥14 days after last dose, supported by PK and off-treatment eGFR data demonstrating resolution of acute eGFR increases occurs within 14 days No association between the magnitude of off-treatment eGFR values and the post-dose period in
Slide 13: Impact of COVID-19
Impact of COVID-19 FDA stated that COVID-19 did not significantly impact treatment visits, data collection, or study drug dispensation 31% of Week 104 assessments were conducted before COVID-19 and 69% of Week 104 assessments were conducted after COVID-19 FDA noted differences for the pre- and post-
Slide 14: Safety
Safety FDA did not communicate significant issues about any safety topics FDA communicated that currently no REMS is expected
Slide 15: Bardoxolone in Other Forms of CKD
Bardoxolone in Other Forms of CKD
Slide 16: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD
FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD Phase 3 similar in design to CARDINAL with two-year treatment duration Based on experience with CARDINAL NDA submission and recent FDA feedback, we will not unblind FALCON until after study completion We noted that we may not be able to sub
Slide 17: MERLIN Phase 2 Study of Bardoxolone in Patients with CKD at Risk for Rapid Progression
Phase 2 trial to evaluate the safety and efficacy of bardoxolone in patients at risk of rapidly progressing CKD due to multiple etiologies Multi-center, double-blind, placebo-controlled eGFR 20-60 mL/min One of the following UACR ≥ 300 mg/g Annual eGFR decline rate ≥ 4 mL/min Hematuria Primary endp
Slide 18: Financial & Operation Update
Financial & Operation Update
Slide 19: Q2 2021 Cash & Shares
Q2 2021 Cash & Shares Cash $755.7M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding 2021 Financial Guidance Based on our operational plans, we anticipate cash runway through mid-2024 Financial Summary 1Excludes stock-based compensation expenses; 2GAAP a
Slide 20: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 21: Concluding Remarks
Concluding Remarks
Slide 22: Reata at a Glance
Reata at a Glance NDA for bardoxolone in Alport syndrome under review; Mid-cycle communication meeting completed; PDUFA date Feb 2022 FALCON enrolled >370 patients; protocol to be amended FDA granted pre-NDA meeting for omaveloxolone in FA scheduled for Q3 2021; plan to submit NDA during Q1 2022 Upd
Slide 23: Thank you
Thank you
Reata Pharmaceuticals — Q2 2021 Earnings Presentation on 6ix